Iron deficiency and pulmonary arterial hypertension.
Nutr Clin Pract
; 37(5): 1059-1073, 2022 Oct.
Article
em En
| MEDLINE
| ID: mdl-35748341
ABSTRACT
The purpose of this review article is to provide a comprehensive review of iron deficiency in the setting of pulmonary arterial hypertension (PAH) and to evaluate the utility of iron supplementation in PAH. Iron deficiency is present in 33%-46% of patients with PAH and has been associated with reduced exercise capacity, compromised oxygen handling, deterioration of right ventricular function, and even mortality. Iron homeostasis and the pathophysiology of PAH are highly intertwined, which has inspired the use of iron supplementation in patients with iron deficiency and PAH. A literature search was performed to identify all available evidence on iron supplementation for PAH. Limited evidence has suggested poor oral bioavailability of oral iron dosed three times a day, but newer formulations such as ferrous maltol may provide better absorption and clinical benefit, especially when dosed less frequently, such as every other day. Intravenous (IV) iron has been shown in observational studies to improve outcomes, but the single randomized control trial in patients without anemia has failed to show benefits in any measure of exercise tolerance. Larger randomized control studies on oral iron with good bioavailability or IV iron in patients with anemia are warranted to explore the potential utility of iron supplementation in patients with PAH.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Hipertensão Arterial Pulmonar
/
Deficiências de Ferro
/
Hipertensão Pulmonar
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Observational_studies
Limite:
Humans
Idioma:
En
Revista:
Nutr Clin Pract
Assunto da revista:
CIENCIAS DA NUTRICAO
/
ENFERMAGEM
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos